Bray Christina Elaine, a director at BioLargo, Inc., has exercised stock options that could signal her confidence in the company's future. The filing, made on October 2, 2026, reveals that Bray acquired 234,375 shares of common stock at an exercise price of $0.08 per share. This transaction, dated September 30, 2026, is part of her compensation for services rendered on the board of directors.

This exercise of stock options is significant as it reflects the ongoing engagement and commitment of directors within the chemical industry, particularly at BioLargo, which specializes in innovative chemical products and services. The company continues to navigate a competitive landscape, and such actions by its directors may influence investor confidence and perceptions of the company's trajectory.

Background

BioLargo, Inc. is a company incorporated in Delaware, primarily engaged in the chemicals and allied products sector, as indicated by its Standard Industrial Classification (SIC) code of 2800. The company operates out of Westminster, California, and focuses on industrial applications and services. BioLargo has undergone several name changes in its history, previously known as Nuway Medical Inc and Latin American Casinos Inc.

What the Filing Says

The filing states, "This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan." This indicates that the options were part of a structured compensation plan aimed at aligning the interests of the directors with those of the shareholders.

Impact

The recent transaction may affect various stakeholders, including current and potential investors, employees, and other directors within BioLargo. The exercise of these options suggests a belief in the company's strategic direction and financial health, which could have implications for investor sentiment and market performance.

What's Next

The filing does not say what happens next.